Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

CARsgen Therapeutics Holdings Ltd. (2171) Stock Price & Analysis

3 Followers

2171 Stock Chart & Stats

HK$11.26HK$0.04(3.40%)
At close: 4:00 PM GMT+8
HK$12HK$14HK$16Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 11.19 - HKD 11.50
52-Week Range
HKD 10.25 - HKD 28.60
Previous Close
HKD 10.89
Volume
N/A
Average Volume (3M)
1.43M
Market Cap
HKD 6.69B
Enterprise Value
HKD 6.32B
Total Cash (Recent Filing)
HKD 1.40B
Total Debt (Recent Filing)
HKD 71.98M
Price to Earnings (P/E)
―
Beta
1.41
Next Earnings
Mar 23, 2027 (Est.)
EPS Estimate
-0.18
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Profit Growth

Revenue rose about 64% to ~122.4M in 2025 and gross profit reached ~49.1M, showing improved commercial traction. If sustained, this scale-up can strengthen operating leverage and provide a larger base from which the company can fund its oncology pipeline.

Lower Debt And Substantial Assets

Debt declined sharply while total assets remained substantial, reducing leverage pressure relative to the prior year. This provides some financial resilience and preserves flexibility for research, development and commercialization, although continued losses could weaken that position over time.

Integrated CAR-T Development Platform

CARsgen operates across the CAR-T value chain, from discovery and preclinical work through clinical development, manufacturing and commercialization. This integrated model can support control over program execution and enable multiple candidates and related technologies to progress through development.

Bears Say

Persistent Operating And Net Losses

The company remains materially loss-making even after revenue and gross profit improved, indicating that operating expenses still substantially exceed its current commercial scale. Persistent EBIT and net losses limit internally funded growth and leave profitability dependent on further expansion or cost improvement.

Ongoing Negative Operating Cash Flow

Operating cash flow remains deeply negative, so the business is not yet funding its operations and research spending internally. Although the burn improved from 2024, continued cash consumption can require financing and may constrain the pace of development or commercialization if sustained.

Material Equity Erosion

The sustained decline in equity is consistent with repeated losses and cash burn, reducing the financial cushion available to support long-term investment. If erosion continues, the company could have less flexibility to absorb setbacks, fund its pipeline and maintain development activity.

CARsgen Therapeutics Holdings Ltd. News

2171 FAQ

What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$10.25 and its highest was HK$28.60 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$6.69B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 132 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 19, 2026. The company reported -HK$0.152 earnings per share for the quarter, beating the consensus estimate of -HK$0.222 by HK$0.07.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Undervalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.18.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 594,248,900 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.152 in its last earnings report, beating expectations of -HK$0.222. Following the earnings report the stock price went up 1.361%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology